Detalhe da pesquisa
1.
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
JAMA
; 330(24): 2354-2363, 2023 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37976072
2.
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
JAMA
; 329(11): 888-897, 2023 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807465
3.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
Clin Infect Dis
; 73(1): 33-42, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33336698
4.
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
Liver Int
; 40(5): 1042-1051, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31765046
5.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Clin Infect Dis
; 68(4): 535-544, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30184165
6.
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
J Viral Hepat
; 26(6): 675-684, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739366
7.
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
J Viral Hepat
; 26(9): 1127-1138, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31108015
8.
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
J Gastroenterol Hepatol
; 34(9): 1597-1603, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30779220
9.
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.
J Gastroenterol Hepatol
; 34(1): 12-21, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30311701
10.
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
Am J Gastroenterol
; 113(6): 863-871, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695828
11.
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Antimicrob Agents Chemother
; 60(5): 2782-9, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26902761
12.
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Antimicrob Agents Chemother
; 59(7): 3816-22, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25870057
13.
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
J Antimicrob Chemother
; 69(3): 573-81, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24128669
14.
Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Antimicrob Agents Chemother
; 57(9): 4172-80, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23774428
15.
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Antimicrob Agents Chemother
; 57(11): 5500-8, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23979732
16.
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
J Infect Dis
; 206(7): 1002-11, 2012 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22896665
17.
In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068.
Antimicrob Agents Chemother
; 56(7): 3498-507, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22547625
18.
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
J Acquir Immune Defic Syndr
; 91(1): 68-72, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35972855
19.
Effect of Ivermectin 600 µg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.
medRxiv
; 2022 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36561174
20.
Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Antimicrob Agents Chemother
; 55(2): 722-8, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21078951